Loading patent…
AssigneesThe United States Government as represented by the Department of Veterans Affairs, East Tennessee State University Research Corporation
InventorZhi Q. Yao
Estimating the term…
Disclosed are exosomes comprising a Na+ taurocholate co-transporting polypeptide (NTCP) binding motif, such as HBV preS1 peptide (PSIP). Disclosed are methods of making exosomes that have been engineered to express a heterologous binding motif on the surface of the exosome, wherein the heterologous binding motif is a NTCP binding motif. Disclosed are methods of treating a subject infected with hepatitis B virus (HBV) comprising administering to the subject a therapeutically effective amount of an exosome, wherein the exosome comprises a NTCP binding motif and a therapeutic agent, thereby treating the HBV infection or any other liver diseases including liver cancer in the subject.
An exosome comprising a Na+ taurocholate co-transporting polypeptide (NTCP) binding motif.
The exosome of any of the preceding claims, further comprising a therapeutic agent.
The exosome of any of the preceding claims, wherein the exosomes have a diameter of about 30-160 nm.
A method of making an engineered exosome comprising:
A method of treating a subject infected with hepatitis B virus (HBV) comprising administering to the subject a therapeutically effective amount of exosomes, wherein the exosomes comprise a NTCP binding motif and a therapeutic agent, thereby treating the HBV infection in the subject.
A method of inactivating HBV cccDNA in HBV infected cells comprising administering to the HBV infected cells a therapeutically effective amount of exosomes, wherein the exosomes comprise an extracellular NTCP binding motif and a therapeutic agent, thereby inactivating HBV cccDNA and/or iDNA in the HBV infected cells.
A method of delivering a therapeutic agent to a HBV target cells comprising administering to the HBV infected cells a therapeutically effective amount of exosomes, wherein the exosomes comprise a NTCP binding motif and a therapeutic agent.
A method of reducing HBV production from cells infected with HBV comprising administering to the HBV infected cells a therapeutically effective amount of exosomes, wherein the exosomes comprise a NTCP binding motif and a therapeutic agent, thereby reducing HBV production in the cells infected with HBV.
A method of cleaving a HBV genome in a cell infected with HBV comprising administering to the HBV infected cells a therapeutically effective amount of exosomes, wherein the exosomes comprise a NTCP binding motif and a therapeutic agent, wherein the therapeutic agent is a HBV specific gRNA/Cas ribonucleoprotein complex comprising a HBV specific gRNA and a Cas protein, thereby cleaving the HBV genome in the cell infected with HBV.
A method of inhibiting HBV replication in HBV infected cells comprising administering to the HBV infected cells a therapeutically effective amount of exosomes, wherein the exosomes comprise a NTCP binding motif and a therapeutic agent, thereby inhibiting HBV replication in the cell.
A gRNA comprising any one of the sequences of Table 1, Table 2, or Table 3.
A gRNA/Cas ribonucleoprotein complex comprising a gRNA and a Cas protein, wherein the gRNA comprises one or more of the sequences of Table 1, Table 2, or Table 3.
Dependencies are inferred from the claim text.